云南白药拟收购聚药堂100%股权，作价6.6亿元

Core Viewpoint - Yunnan Baiyao announced the acquisition of 100% equity in Juyatang Pharmaceutical Co., Ltd. for a total consideration of 660 million yuan to enhance the development of the traditional Chinese medicine industry in Yunnan Province and expand its business nationwide [1] Group 1: Acquisition Details - The acquisition is aimed at responding to the Yunnan provincial government's call for high-quality development in the traditional Chinese medicine industry [1] - The total consideration for the acquisition is 660 million yuan [1] - Juyatang specializes in the production and sales of traditional Chinese medicine pieces, toxic traditional Chinese medicine pieces, directly consumable traditional Chinese medicine pieces, and formula granules [1] Group 2: Strategic Objectives - The acquisition aligns with the company's strategic development goals to boost the sales of traditional Chinese medicine within Yunnan Province [1] - The move is expected to facilitate the nationwide expansion of Yunnan Baiyao's related business operations [1] - The company aims to enhance the collaborative efficiency of the traditional Chinese medicine industry chain through this acquisition [1]